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Abstract
Ether glycerolipids of Leishmania major are important membrane components as well as building blocks of various virulence
factors. In L. major, the first enzyme of the ether glycerolipid biosynthetic pathway, LmDAT, is an unusual, glycosomal
dihydroxyacetonephosphate acyltransferase important for parasite’s growth and survival during the stationary phase,
synthesis of ether lipids, and virulence. The present work extends our knowledge of this important biosynthetic enzyme in
parasite biology. Site-directed mutagenesis of LmDAT demonstrated that an active enzyme was critical for normal growth
and survival during the stationary phase. Deletion analyses showed that the large N-terminal extension of this initial
acyltransferase may be important for its stability or activity. Further, abrogation of the C-terminal glycosomal targeting
signal sequence of LmDAT led to extraglycosomal localization, did not impair its enzymatic activity but affected synthesis of
the ether glycerolipid-based virulence factor lipophosphoglycan. In addition, expression of this recombinant form of LmDAT
in a null mutant of LmDAT did not restore normal growth and survival during the stationary phase. These results emphasize
the importance of this enzyme’s compartmentalization in the glycosome for the generation of lipophosphoglycan and
parasite’s biology.
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Introduction
Worldwide Leishmania parasites cause important human and
animal diseases collectively called leishmaniasis. Disease transmis-
sion occurs upon biting by an infected female sand fly. The
parasite develops extracellularly as flagellated promastigotes in the
midgut of the insect vector, and intracellularly as non motile
amastigotes within the phagolysosomal compartment of the
vertebrate host’s macrophages. L. major is responsible for the
cutaneous form of leishmaniasis which manifests in a local self-
healing skin lesion and affects approximately 1–1.5 million patients
every year [1]. Ninety percent of cases of cutaneous leishmaniasis
are found in Afghanistan, Pakistan, Syria, Saudi Arabia, Algeria,
Iran, Brazil, and Peru [1].
Ether glycerolipids are major components of Leishmania
membranes, representing approximately 20% of total cellular
lipids [2,3]. In Leishmania major, they are found primarily in the
phosphatidylethanolamine and phosphatidylinositol glycerolipids
[2,3,4,5]. They are of particular importance for this parasite
because ether glycerolipid based virulence factors such as
lipophosphoglycan (LPG) and glycosylphosphatidylinositol-an-
chored proteins play critical roles throughout its life cycle
(reviewed in [6,7,8,9,10]). Structurally, LPG is a complex
glycolipid that is anchored to the plasma membrane via an ether
lysophosphatidylinositol anchor [11]. The salient feature of LPG
is the conserved domain consisting of the Galb1,4Mana1-PO4
backbone of repeat units that in L. major are branched with
galactose and arabinose residues [6,9,12,13,14].
In Leishmania, ether lipid biosynthesis initiates with the acylation
of dihydroxyacetonephosphate (DHAP) by the DHAP acyltrans-
ferase (DHAPAT) LmDAT, an obligatory step for the biosynthesis
of ether lipids ([4,15,16]; Fig. 1). The product of this first
acylation reaction, 1-acyl-DHAP, is then converted to 1-alkyl-
DHAP by the alkyl DHAP synthase ADS1, which is further
reduced to 1-alkyl-glycerol-3-phosphate (1-alkyl-G3P) by a
NADPH-dependent alkyl/acyl-DHAP reductase [2,17]. The
intermediate 1-alkyl-G3P serves as the obligate precursor for all
ether glycerolipids. Alternatively, in the absence of the G3P
acyltransferase LmGAT, 1-acyl-DHAP can be reduced to 1-acyl-
G3P by a NADPH-dependent alkyl/acyl-DHAP reductase,
which is subsequently used for the biosynthesis of ester
glycerolipids [18]. The DHAPAT and alkyl-DHAP synthase are
sequestered in the peroxisome-like organelle, called glycosome in
Leishmania and related parasites [2,16,19], while the acyl/alkyl-
DHAP reductase is associated with the glycosomes but its active
site faces the cytoplasm [17].
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terminal extension of approximately 650 amino acids that is absent
in mammalian orthologs [16]. Our previous studies demonstrated
that LmDAT is important for growth, survival during stationary
phase, the synthesis of ether lipids that includes the ether lipid
based LPG, and for virulence, but is dispensable for raft formation
[2,4,15]. All together, these data support the notion that LmDAT
may represent a potential target for anti-leishmanial chemother-
apy. In the present work, a rational deletion approach was applied
i) to address the role of the N-terminal extension of LmDAT in
enzyme stability and activity, and ii) to investigate the significance
of LmDAT glycosomal localization in the synthesis of the ether
lipid based LPG. Last, point mutation analysis was carried out to
assess whether a catalytically active LmDAT enzyme is required to
support normal growth and survival during the stationary phase of
the parasite.
Materials and Methods
Strains and growth conditions
Promastigotes of L. major Friedlin V1 strain (MHOM/IL/80/
Friedlin) were propagated in liquid and semi-solid M199-derived
medium [2]. The null mutant Dlmdat/Dlmdat and complemented
line Dlmdat/Dlmdat [LmDAT NEO] were described in [4].
Transfection was performed according to Ngo and colleagues
[20] and selection was applied as appropriate in the presence of
20–40 mg/ml G418 or 25–50 mg/ml of hygromycin. To follow
parasite proliferation, mid log phase parasites were diluted to
5610
5/ml and enumerated with a hemacytometer as a function of
time.
Plasmids
Deletion constructs of LmDAT were created by polymerase
chain reaction (PCR) using pL-BSD.LmDAT [16] as a template,
and the primer pairs O33 (‘5-CCGGGATCCCATATGA-





The resulting amplified DNA fragments were digested with BamHI,
and ligated in sense orientation into the BamHI sites of pXG.HV-
LmDAT [16] to yield pXG.HV-LmDAT-DC733 (Ec395), pXG.HV-
DN546-LmDAT (Ec569), and pXG.HV-DN686-LmDAT (Ec571),
respectively.
The plasmid for the expression of a truncated form of LmDAT,
lacking the C-terminal glycosomal targeting tripeptide SKM
(LmDAT-DC3) was generated by PCR using the oligonucleotides
O34 (‘5-CCGGGATCCCATATGAGCTTCCCACCACCTC-
GG-3’) and O112 (‘5-CGGGATCCTCATGGCTGTGTTAGC-
TCACGG-3’), and pL-BSD.LmDAT as a template. The obtained
DNA fragment was subsequently digested with BamHI and cloned
as a 4.3 kb fragment in sense orientation into the respective sites of
pXG.HV-LmDAT to give pXG.HV-LmDAT-DC3 (Ec440).
The K852L mutant form of LmDAT was created by introducing
the point mutation by PCR using oligonucleotides O133 (‘5-
AGGAAAGCTTCATAAAGAGGGCGCCGCTG-3’) and O134
(‘5-TATGAAGCTTTCCTTCCTTCCGCGACGACCCG-3’),
and pL-BSD.LmDAT as a template. In addition, a HindIII site
was introduced to ‘‘tag’’ the mutation. The mutated fragment
was swapped with the corresponding wild-type DNA using the
SacIa n dMluI sites of pBEVY-L.LmDAT described in [16] to
give pBEVY-L.LmDAT
K852L (Ec276). This plasmid was
subsequently digested with BamHI and the excised 4.3 kb
fragment was ligated in sense orientation into the respective
sites of pXG.HV-LmDAT [16] to yield pXG.HV-
LmDAT
K852L (Ec456). All amplified DNAs were verified by
sequencing.
The plasmids pXG.HV-LmDAT [16], pXG.HV-LmDAT-
DC733, pXG.HV-DN546-LmDAT, pXG.HV-DN686-LmDAT,
pXG.HV-LmDAT
K852L, and pXG.HV-LmDAT-DC3 were trans-
formed into the null mutant Dlmdat/Dlmdat to give the strains
Dlmdat/Dlmdat [HV-LmDAT NEO], Dlmdat/Dlmdat [HV-LmDAT-
DC733 NEO], Dlmdat/Dlmdat [HV-DN546-LmDAT NEO], Dlmdat/
Dlmdat [HV-DN686-LmDAT NEO], Dlmdat/Dlmdat [HV-LmDAT
K852L
NEO], and Dlmdat/lmdat [HV-LmDAT-DC3 NEO], respectively. In
addition, pXG.HV-LmDAT and pXG.HV-LmDAT-DC3 were
also transformed into the wild type to yield FV1 [HV-LmDAT NEO]
and FV1 [HV-LmDAT-DC3 NEO], respectively.
Enzymatic assays
Leishmania protein extracts were prepared as described previ-
ously [16,18]. Protein concentration was determined by the
bicinchoninic acid assay using bovine serum albumin as a
standard. DHAPAT activity was assessed by measuring the
acylation rate of DHAP produced by catabolism of fructose-1,6-
biphosphate by the action of an aldolase and a triose phosphate
isomerase, based on a protocol established by Bates and Saggerson
as described in [16]. The specificity of [U-
14C]D-fructose-1,6-
biphosphate (MP Biomedicals) was 295 mCi/mmol.
Digitonin fractionation and electrophoresis
For digitonin treatment fresh end-log cells were harvested,
washed once in phosphate buffered saline (PBS), and resuspended
in 20 mM TrisHCl (pH 8.0), 1 mM EDTA, 1 mM DTT
containing a protease inhibitor cocktail (Roche) at a cell density
of 2610
8/ml. Aliquots of 100 ml were made and supplemented
with increasing (0 to 0.6 mg/ml) concentrations of digitonin (stock
solution of 15 mg/ml in PBS) and incubated at 26uC for 10 min.
Cells were then centrifuged at 20,800 g for 2 min. Supernatants
were immediately removed and resolved by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE).
Western blot analyses in the presence of monoclonal WIC79.3
(specific to b-galactose side-chains; generous gift from S. Turco;
[21]) and V5 (Invitrogen) antibodies, and polyclonal immuno-
Figure 1. Glycerolipid biosynthetic pathways in Leishmania. AGAT, 1-acyl-glycerol-3-phosphate acyltransferase; ADR, alkyl/acyl-DHAP
reductase; LmADS, alkyl-DHAP synthase; DHAP, dihydroxyacetonephosphate; LmDAT, DHAP acyltransferase; LmFAR, fatty acyl-CoA reductase; G3P,
glycerol-3-phosphate; LmGAT, G3P acyltransferase; PA, phosphatidic acid. Genes encoding ADR and AGAT in Leishmania are unknown.
doi:10.1371/journal.pone.0027802.g001
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ferase (generous gift from A. Jardim; [22]), phosphomannomutase
(generous gift from L. Kedzierski; [23]), and arginase (generous gift
from B. Ullman; [24]) were carried out as described previously
[2,4].
Immunofluorescence assay
Immunofluorescence assay was performed with wild-type
parasites expressing pXG.HV-LmDAT-DC3 as described previ-
ously [16]. The recombinant His6-V5 (HV) tagged HV-LmDAT-
DC3 was revealed with V5 monoclonal antibodies (Invitrogen) and
hypoxanthine guanine phosphoribosyltransferase was visualized
with specific rabbit polyclonal immunoglobulins [22]. Both
antibodies were used at a 1:500 dilution. Images were taken with
a Leica fluorescence microscope.
Results and Discussion
The N-terminal extension is important for LmDAT activity
Amino acid sequence alignment of DHAPAT enzymes from
human, rat, Caenorhabditis elegans, Trypanosoma brucei and Trypano-
soma cruzi shows that orthologs of parasites of the trypanosomat-
idae family bear a very large N-terminal extension of approxi-
mately 650 amino acids that is absent in higher eukaryotic
orthologs ([16]; Fig. 2A; data not shown). Curiously, this domain
fails to exhibit any similarity to known proteins and thus, is
parasite specific. The function of this N-terminal extension was
first investigated by creating truncated LmDAT versions that were
N-terminally tagged with a hexahistidine fused to a V5 epitope
(HV) for visualization with the V5-specific monoclonal antibody.
Plasmids coding for truncated proteins lacking the N-terminal
546 and 686 amino acids (HV-DN546-LmDAT and HV-DN686-
LmDAT), respectively, were constructed, as well as a plasmid
coding for a recombinant protein missing the 733 C-terminal
amino acids (HV-LmDAT-DC733). In the latter case, the LmDAT
C-terminal tripeptide SKM was fused to the C-terminal portion
of the truncated protein to ensure glycosomal targeting
[25,26,27]. These recombinant proteins, as well as a wild-type
HV tagged version (HV-LmDAT), were expressed in the null
mutant Dlmdat/Dlmdat background [16].
We verified first that the HV tag did not affect the function of
LmDAT; the recombinant protein HV-LmD A Tw a se x p r e s s e da s
an approximately 150 kDa band as shown by Western blot
analysis using the monoclonal antibody specific to the V5
epitope (Fig. 2C). Bands present at lower molecular weights very
likely represent degradation products of the full length tagged
protein. In addition, HV-LmDAT was enzymatically active, and
supported normal growth and survival during the stationary
phase (Fig. 2B, 3A; [16]). The presence of ether lipids was
assessed by investigating the migration behavior of the ether
lipid anchored virulence factor LPG; it has been established that
Leishmania mutants lacking ether lipids synthesize slow migrating
forms of LPG as a result of hyperglycosylation of its disaccharide
domain [2,4]. Western blot analysis showed that HV-LmDAT
restored expression of normal migrating forms of LPG while the
null mutant expressed slower migrating LPG species (Fig. 2D;
[4]).
Deletions of the N-terminal (first 546 or 686 amino acids) but
not of the C-terminal 733 amino acids led to low intensity signals
as shown by Western blot analysis using the monoclonal antibody
specific to the V5 epitope, as the corresponding bands at apparent
weights of approximately 100 and 83 kDa respectively, were
hardly detectable (Fig. 2C). Accordingly, none of the N-terminal
(HV-DN546-LmDAT and HV-DN686-LmDAT) and C-terminal
(HV-LmDAT-DC733) truncated proteins rescued the slow growth
or the rapid death during the stationary phase (Fig. 3A). Consistent
with these results, no DHAPAT activity could be measured with
cells expressing any of these truncated versions of LmDAT
(Fig. 2B). Accordingly, Western blot analyses in the presence of
WIC79.3 for detection of LPG revealed that null mutant strains
expressing any of the three truncated forms of LmDAT made
glycolipids migrating slower than that of the wild type but similar
to that of the null mutant (Fig. 2D; [4]).
Our results show that N-terminal truncated versions of
LmDAT gave lower intensity signals in Western blot analysis
in the presence of anti-V5 antibody. A possible explanation is
that the V5 antibody has lower affinity for these recombinant
proteins or less access to the epitope due to conformation issues.
In this case the N-terminal domain may indirectly be important
for catalysis; because this domain is absent in higher eukaryotic
counterparts (Fig. 2A; data not shown; [16]), it is doubtful that it
is directly involved in substrate recognition or catalysis. These
events are expected to occur in the C-terminal domain of
LmDAT that is shared by all DHAPAT orthologs (Fig. 2A; [16])
and this assumption is corroborated by the fact that HV-
LmDAT-DC733 is inactive. Another possible interpretation is
that the N-terminal domain somehow helps this very large
protein to fold properly in order to yield a stable enzyme, and
thus, affects LmDAT activity indirectly. All together these data
suggest that designing a compound specific to the N-terminal
extension may represent a reasonable strategy to inactivate
LmDAT.
A catalytically active LmDAT enzyme is necessary for
growth and survival during the stationary phase
In contrast to Dlmdat/Dlmdat, the Dads1/Dads1 mutant, carrying
a genetic deletion of the alkyl DHAP synthase gene and lacking
ether lipids, does not exhibit any growth phenotype, suggesting
that ether lipids are dispensable for growth and survival during the
stationary phase [2]. Thus, LmDAT may be a bipartite protein
with an N-terminal domain involved in growth and survival during
the stationary phase, and a C-terminal domain functioning in
catalysis. To assess whether a catalytically active LmDAT
DHAPAT is important for normal growth and survival during
the stationary phase, a mutant enzyme was created that bears a
leucine instead of a lysine at position 852 (K852L), based on the
information that replacement of the corresponding conserved
amino acid by a histidine in the human DHAPAT abrogated its
enzymatic activity [28]. As described above, a HV-tagged version
(HV-LmDAT
K852L) was expressed in the null mutant background.
Western blot analysis was performed to verify its expression level
that was similar to HV-tagged wild-type LmDAT (Fig. 2C). HV-
LmDAT
K852L enzyme displayed no DHAPAT activity and led to
the production of slow migrating LPG glycolipids similar to that of
the null mutant (Fig. 2B, 2D). In addition, HV-LmDAT
K852L failed
to support normal growth and survival during the stationary phase
(Fig. 3B).
Altogether, these results demonstrate that the conserved lysine
K852 is important for substrate recognition or catalysis of LmDAT
similar to the human ortholog. Together with the fact that the N-
terminal domain alone is unable to support normal growth and
survival during the stationary phase, our results suggest that the
acyltransferase activity of LmDAT itself is critical for normal
growth and survival during the stationary phase. Our data also
exclude the idea that LmDAT is a bipartite enzyme with an N-
terminal domain responsible for growth and/or survival during
the stationary phase, and a C-terminal part implicated in
acyltransferase activity.
Leishmania Initial Acyltransferase LmDAT
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synthesis
LmDAT resides in glycosomes consistent with the presence of a
typical type 1 C-terminal glycosomal targeting signal sequence
(SKM), that is sufficient for targeting proteins to this organelle
[16,19]. Hence, the importance of the glycosomal subcellular
localization of LmDAT for ether lipid biosynthesis was assessed by
expressing a HV-tagged LmDAT recombinant enzyme lacking the
C-terminal glycosomal targeting tripeptide SKM (HV-LmDAT-
DC3) in the null mutant background [25,27,29]. Western blot
analysis was performed in the presence of anti-V5 monoclonal
antibodies demonstrated that the levels of HV-LmDAT-DC3
protein were similar to that of wild-type tagged HV-LmDAT
expressed in the null mutant background (Fig. 2C).
Subcellular localization of HV-LmDAT-DC3 was assessed by
immunofluorescence assay. HV-LmDAT-DC3 was revealed in the
presence of V5 monoclonal antibodies and gave a signal that was
partially overlapping with that obtained with antibodies specific to
the glycosomal resident hypoxanthine guanine phosphoribosyl-
transferase suggesting a glycosomal association ([22]; Fig. 4).
However, digitonin fractionation provided evidence for HV-
LmDAT-DC3 localizing outside the glycosomes. Digitonin specif-
Figure 2. Characterization of mutant forms of LmDAT. (A) Schematic representation of human DHAPAT (hDHAPAT) and mutant forms of
LmDAT. The grey rectangle, the black rectangle and the hatched area depict the HV tag, the conserved domain, and the C-terminal glycosomal
targeting tripeptide, respectively, and the asterisk depicts the point mutation. B) DHAPAT activity was quantified as described in Materials and
Methods. Equivalent of 0.5 mg protein extracts were applied for the assay. Null mutant alone or expressing HV-tagged wild-type and mutant forms of
LmDAT were used as a source of protein extracts. Activity is expressed as percentage of the positive control, the wild type (WT). The assay was
performed twice in duplicate, and the graph depicts one representative experiment. Standard deviations are shown. (C) Western blot analyses in the
presence of V5-specific (upper; V5) and hypoxanthine guanine phosphoribosyltransferase specific (lower; HGPRT; loading control) antibodies.
Equivalent of 5610
7 cells were loaded in each lane. The apparent molecular weight is shown on the left. (D) Western blot analysis in the presence of
WIC79.3 antibody to detect LPG. Equivalent of 10
6 cells were loaded in each lane. (B, C, D): 1, Dlmdat/Dlmdat;2 ,Dlmdat/Dlmdat [HV-LmDAT NEO];3 ,
Dlmdat/Dlmdat [HV-DN546-LmDAT NEO];4 ,Dlmdat/Dlmdat [HV-DN686-LmDAT NEO];5 ,Dlmdat/Dlmdat [HV-LmDAT-DC733 NEO];6 ,Dlmdat/Dlmdat [HV-
LmDAT-DC3 NEO];7 ,Dlmdat/Dlmdat [HV-LmDAT
K852L NEO]; WT, wild type.
doi:10.1371/journal.pone.0027802.g002
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tions while high doses of this detergent are needed to solubilize the
glycosomal membrane [30]. HV-LmDAT required a minimal
concentration of digitonin of 0.45 mg/ml in order to be properly
released in the cell supernatant and behaved similarly as the
glycosomal resident arginase ([31]; Fig. 5), In contrast, HV-
LmDAT-DC3 readily fractionated in the cell supernant at a low
digitonin concentration of 0.075 mg/ml, as the cytosolic enzyme
phosphomannomutase [23]. Our data suggest that HV-LmDAT-
DC3 is partially associated with glycosomes and possibly other
organelles but resides on the cytosolic side of the organellar
membrane. This is consistent with previous studies that demon-
strated that abrogation of the type 1 C-terminal glycosomal
targeting signal sequence resulted in a cytoplasmic localization
[25,27,29].
In vitro DHAPAT assays showed that HV-LmDAT-DC3 was
enzymatically active as the wild-type HV-tagged version of
LmDAT (Fig. 2B), demonstrating that the C-terminal glycosomal
targeting sequence is dispensable for enzymatic activity. Surpris-
ingly, Western blot analysis performed in the presence of WIC79.3
demonstrated that, in contrast to HV-LmDAT, HV-LmDAT-DC3
expression failed to restore the synthesis of normal migrating LPG
(Fig. 2D). Consistent with this result, expression of HV-LmDAT-
DC3 did not ameliorate the slow growth and survival during the
stationary phase of the null mutant (Fig. 3B). These data suggest
that the proper acyl donor for LmDAT, palmitoyl-CoA, may not
be available in the cytosol [16]. This is unlikely because fatty acyl-
CoAs are made either in the endoplasmic reticulum by elongases
or in the mitochondria by type II fatty acyl-CoA synthases, and
have to be transported via the cytosol to the endoplasmic reticulum
and glycosomes where lipid biosynthesis occurs [16,32,33,34].
Alternatively, the role of the glycosomal compartmentalization of
Figure 3. Growth curves. Cells were inoculated at a cell density of
5610
5/ml and were enumerated with a hemacytometer as a function of
time. The assay was performed twice and the graphs represent a typical
experiment. Standard deviations are shown. (A) Black circles, wild type;
grey circles, complemented line Dlmdat/Dlmdat [HV-LmDAT NEO]; white
circles, Dlmdat/Dlmdat; white triangles, Dlmdat/Dlmdat [HV-DN546-
LmDAT NEO]; grey triangles, Dlmdat/Dlmdat [HV-DN686-LmDAT NEO];
black triangles, Dlmdat/Dlmdat [HV-LmDAT-DC733 NEO]. (B) Black circles,
wild type; grey circles, complemented line Dlmdat/Dlmdat [HV-LmDAT
NEO]; white circles, Dlmdat/Dlmdat; white triangles, Dlmdat/Dlmdat




Figure 4. HV-LmDAT-DC3 does not localize in the glycosomes.
Wild type expressing recombinant HV-LmDAT-DC3 was analyzed by
phase contrast (panel 1) or immunofluorescence microscopy using anti-
V5 antibody (panel 2) or polyclonal antiserum specific to hypoxanthine
guanine phosphoribosyltransferase (panel 3). Panel 4 shows the merge
of panels 2 and 3.
doi:10.1371/journal.pone.0027802.g004
Figure 5. Digitonin fractionation followed by Western blot
analysis. FV1 [HV-LmDAT NEO] and FV1 [HV-LmDAT-DC3 NEO] were
fractionated in the presence of digitonin as described in Materials and
Methods. Cell supernatants were then subjected to Western blot
analysis in the presence of monoclonal anti-V5 antibodies (V5), and of
polyclonal immunoglobulins specific to arginase (ARG) and phospho-
mannomutase (PMM). Equivalent of 10
7 cell supernants were loaded in
each lane. The apparent molecular weight markers are shown.
doi:10.1371/journal.pone.0027802.g005
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for conversion into 1-alkyl-DHAP by the glycosomal alkyl DHAP
synthase ADS1 rather than being metabolized to 1-acyl-G3P by
the cytosolic alkyl/acyl-DHAP reductase for the synthesis of ester
glycerolipids [2,17]. Last, DHAP produced in the glycosome may
not be available in the cytosol where HV-LmDAT-DC3 accumu-
lates [19]. These results are also in accordance with the idea that
the glycosomal membrane does not allow transport of 1-acyl-
DHAP from the cytosol into the glycosome for conversion to 1-
alkyl-DHAP by the alkyl-DHAP synthase ADS1.
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